165 related articles for article (PubMed ID: 11911506)
21. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
[TBL] [Abstract][Full Text] [Related]
22. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
23. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
24. Fulvestrant and the sequential endocrine cascade for advanced breast cancer.
Johnston S
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S15-8. PubMed ID: 15094760
[TBL] [Abstract][Full Text] [Related]
25. Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?
Johnston SR
Breast Cancer Res; 2005; 7(3):119-30. PubMed ID: 15987442
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor downregulators: new advances in managing advanced breast cancer.
Lynn J
Cancer Nurs; 2002 Apr; 25 Suppl 2():2S-5S; quiz 18S-19S. PubMed ID: 12080537
[TBL] [Abstract][Full Text] [Related]
27. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
Dowsett M; Nicholson RI; Pietras RJ
Breast Cancer Res Treat; 2005; 93 Suppl 1():S11-8. PubMed ID: 16247595
[TBL] [Abstract][Full Text] [Related]
28. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
29. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
30. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Chia S; Gradishar W
Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
[TBL] [Abstract][Full Text] [Related]
31. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
Robertson JF
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):209-12. PubMed ID: 11850227
[TBL] [Abstract][Full Text] [Related]
32. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
[TBL] [Abstract][Full Text] [Related]
33. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
Osipo C; Gajdos C; Liu H; Chen B; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1597-608. PubMed ID: 14600092
[TBL] [Abstract][Full Text] [Related]
34. Fulvestrant.
Curran M; Wiseman L
Drugs; 2001; 61(6):807-13; discussion 814. PubMed ID: 11398912
[TBL] [Abstract][Full Text] [Related]
35. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
36. [Fulvestrant: a new agent in endocrine treatment for breast cancer].
Juretić A; Sarić N; Bisof V; Basić-Koretić M
Lijec Vjesn; 2006; 128(1-2):31-6. PubMed ID: 16640225
[TBL] [Abstract][Full Text] [Related]
37. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
38. Current and future perspectives on fulvestrant.
Gradishar WJ; Sahmoud T
Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S23-9. PubMed ID: 15865847
[TBL] [Abstract][Full Text] [Related]
39. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
[TBL] [Abstract][Full Text] [Related]
40. Preliminary experience with pure antiestrogens.
Howell A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4369s-4375s; discussion 4411s-4412s. PubMed ID: 11916227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
